JIANG, LEIHANG – Trademark Portfolio

Entity Type: 01

JIANG, LEIHANG holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include YUBINE and ASHIELIY. The owner is based in SICHUAN PROVINCE.

TOWN, WUSHENG COUNTY

NO.14, GROUP 7, GUHUA VILLAGE, SANXI

SICHUAN PROVINCE 638400 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ASHIELIY
ASHIELIY
Registered 2023
YUBINE
YUBINE
Registered 2020

Trademark Classifications

JIANG, LEIHANG's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does JIANG, LEIHANG have?

JIANG, LEIHANG has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does JIANG, LEIHANG file in?

JIANG, LEIHANG files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are JIANG, LEIHANG's most well-known trademarks?

JIANG, LEIHANG's registered trademark portfolio includes well-known marks such as YUBINE and ASHIELIY. These are among 2 currently registered trademarks in the portfolio.

What is JIANG, LEIHANG's trademark registration success rate?

JIANG, LEIHANG has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.